Alkermes (ALKS) Long-Term Debt Repayments (2012 - 2024)
Alkermes (ALKS) posted quarterly Long-Term Debt Repayments of $750000.0 for Q3 2024, little changed year-over-year from $750000.0 in Q4 2023, and little changed quarter-over-quarter from $750000.0 in Q2 2024.
Alkermes (ALKS) Long-Term Debt Repayments (2012 - 2024) Analysis & Trends
Alkermes (ALKS) has reported Long-Term Debt Repayments for 13 consecutive years, with $750000.0 the latest figure, recorded in Q3 2024.
- In Q3 2024, Long-Term Debt Repayments changed 0.0% year-over-year to $750000.0; the TTM figure through Dec 2024 stood at $2.2 million (down 25.0% YoY), while the FY2024 annual figure was $2.2 million, down 25.0% from the prior year.
- Long-Term Debt Repayments steadied at $750000.0 in Q3 2024 per ALKS's latest filing, from $750000.0 in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $750000.0 in Q3 2021 and bottomed at $710000.0 in Q2 2020.
- Historically, Long-Term Debt Repayments has averaged $740764.7 across 5 years, with a median of $750000.0 in 2021.
- Annual changes were most pronounced in 2020 — Long-Term Debt Repayments changed 0.0% — and 2021, when it rose 5.49%.
- Alkermes' Long-Term Debt Repayments stood at $711000.0 in 2020, then grew by 5.49% to $750000.0 in 2021, then changed by 0.0% to $750000.0 in 2022, then changed by 0.0% to $750000.0 in 2023, then changed by 0.0% to $750000.0 in 2024.
- Business Quant data shows ALKS's Long-Term Debt Repayments at $750000.0 in Q3 2024, $750000.0 in Q2 2024, and $750000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -156,847.56 |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.02 Bn | 7.37 Bn | 397.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 750,000.00 |
| Sep 30, 2024 | 750,000.00 |
| Jun 30, 2024 | 750,000.00 |
| Jun 30, 2024 | 750,000.00 |
| Mar 31, 2024 | 750,000.00 |
| Mar 31, 2024 | 750,000.00 |
| Dec 31, 2023 | 750,000.00 |
| Dec 31, 2023 | 750,000.00 |
| Sep 30, 2023 | 750,000.00 |
| Sep 30, 2023 | 750,000.00 |
| Jun 30, 2023 | 750,000.00 |
| Jun 30, 2023 | 750,000.00 |
| Mar 31, 2023 | 750,000.00 |
| Mar 31, 2023 | 750,000.00 |
| Dec 31, 2022 | 750,000.00 |
| Dec 31, 2022 | 750,000.00 |
| Sep 30, 2022 | 750,000.00 |
| Sep 30, 2022 | 750,000.00 |
| Jun 30, 2022 | 750,000.00 |
| Jun 30, 2022 | 750,000.00 |